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ABSTRACT
The paraventricular nucleus of the hypothalamus (PVN) plays a critical role in
regulating the hypothalamic-pituitary-adrenal (HPA) axis, sympathetic activity,
cardiovascular system and stress responses.1,2 This brain region is primarily controlled
by GABA and glutamate inputs from the peri-PVN region.3 Two significant
modulators of these GABA-glutamate systems are Angiotensin II (Ang II) and brain
derived neurotrophic factor (BDNF). It has been postulated that BDNF and Ang II
signaling rely on each other via cross-activation of their receptors and by activation of
the non-selective cation channel, the transient receptor channel type C3 (TRPC3).
This thesis aims to study changes in intracellular calcium levels as an indicator of
neuronal activity in the PVN, and to investigate the role of Ang II, BDNF and TRPC3
mediated mechanisms. Five-week-old rats were injected with AAV2-CaMP6f to
visualize intracellular calcium in PVN neurons with a multi-photon microscope. We
developed tools to analyze changes in calcium signals, which employed mathematical
algorithms to determine regions of interest (ROIs) based on variability of GCaMP6f
fluorescence. Calcium signals were analyzed using the number of active sites, or
ROIs, average intensity and cumulative intensity of all ROIs within the field of view.
Time control experiments demonstrated that neurons in our preparation displayed
“spontaneous” activity and were not significantly affected by prolonged laser
exposure. In addition, we found that inhibition of sodium channels with TTX,
administration of GABA and the L-type calcium channel inhibitor nifedipine
significantly blocked PVN neuronal calcium events. An inhibitory cocktail of
biciculline (GABAA antagonist), AP-5 (NMDA receptor antagonist) and CNQX
(AMPA receptor antagonist) was used to block peri-PVN input, and overall decreased
the number active sites present, while the average intensity was unchanged. We found
no significant changes in our measured parameters in response to Ang II, activation of
the BDNF receptor and activation or inhibition of TRPC3 channels.
These results demonstrate the potential of this new method to study and analyze
calcium changes in PVN neurons. We were able to show that neuronal activity can be
successfully inhibited by TTX, GABA and nifedipine. However, the role of TRPC3
and the interaction between BDNF and Ang II remains unclear.
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1. Overview of the Hypothalamus
The hypothalamus, as described by its Greek name, hypo meaning below and
thalamus meaning bed, is part of the forebrain that lies beneath the thalamus. Galen of
Pergamon first described its role in the 2nd century AD as a route for mucus to move
from the brain to the nasopharynx. It wasn’t until the 14th century that the third
ventricle was described as an area of integration for homeostatic function. The
neurosecretory function of the hypothalamus was then generally outlined in 1928.
Meanwhile, the pituitary gland that lies right below the hypothalamus wasn’t
understood as a secretory organ connected to the hypothalamus until the mid 18th
century.4
The hypothalamus is a critical integrating brain region that modulates homeostatic
functions including blood pressure regulation, thermoregulation, metabolism,
hormonal control and stress responses.5 This brain region can be divided into three
segments: rostral, medial and posterior. The rostral segment is made up of the
preoptic area, including the suprachiasmatic nucleus as well as the median and
ventrolateral preoptic nuclei, which play a role in several integrative processes such as
sexual behavior, wake-sleep patterns and thermoregulation.5,6 The medial segment
overlies the pituitary gland and consists of the dorsomedial, ventromedial, supraoptic,
arcuate and paraventricular nuclei.5 This region is involved in key autonomic and
endocrine processes.6 Lastly, the posterior segment is made up of mammillary nuclei
and the posterior area, which are responsible for stress responses and wakefulness.5,6
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1.1 The Paraventricular nucleus of the hypothalamus- Anatomy and Function
The paraventricular nucleus (PVN) lies within the medial segment of the
hypothalamus and is located on both sides of the third ventricle.1 Neurons within the
PVN have extensive connections to other regions of the hypothalamus, as well as the
limbic system, brainstem and prefrontal cortex.1 The PVN is comprised of two
different groups of neurons: magnocellular neurons and parvocellular neurons.7 The
population of magnocellular neurons project into the posterior pituitary and are
directly involved in the synthesis and release of oxytocin and vasopressin.1,7 This
group of neurons is characteristically larger than their parvocellular counterparts. 7 The
parvocellular neurons of the PVN project into areas of the central nervous system and
anterior pituitary gland.7,8 These neuroendocrine cells secrete either activating or
inhibitory hormones onto the anterior pituitary, thereby controlling its secretions.6
Regulating hormones secreted from the parvocellular neurons include corticotropinreleasing hormone (CRH), thyrotropin-releasing hormone (TRH), somatostatin and
dopamine, which trigger adrenocorticotropin, thyroid stimulating hormone, growth
hormone and prolactin release from the anterior pituitary respectively. 9 The
parvocellular neurons of the PVN also play a crucial role in regulating sympathetic
activity through their projections into the rostral ventrolateral medulla (RVLM),
nucleus tractus solitarius (NTS), pontine parabrachial nucleus, intermediolateral
column of the spinal cord and pre-ganglionic sympathetic neurons.10 PVN neurons
can be activated by a variety of inputs, like those from the cortex or amygdala, as well
as increases in circulating factors such as cytokines or sodium to trigger increases in
sympathetic activity.10
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1.2 Regulation of PVN activity
Paraventricular neuronal excitation and inhibition is primarily regulated by local
circuitry that lies just outside the PVN. The activity of peri-PVN neurons is controlled
by GABA-ergic and glutamatergic afferents.3 Inhibitory GABA-ergic inputs are
distributed laterally around the PVN, and also extend up from the base of the
hypothalamus, ventral to the PVN.8 The lateral septum and amygdala (limbic system)
have GABA-ergic afferents, which synapse onto local GABA-ergic neurons, leading
to PVN disinhibition. On the contrary, the ventral subiculum, prefrontal cortex and
the suprachiasmatic nuclei send glutamatergic (excitatory) afferents onto local
GABA-ergic neurons thus inhibiting the PVN. In addition, glutamate can act on
NMDA, AMPA and kainate receptors expressed in the PVN itself. 3 There is also
evidence demonstrating the presence of acetylcholine and serotonin afferents, which
synapse onto local glutamatergic neurons projecting into the PVN as well, though
these inputs are weaker.3

1.3 The PVN in the Regulation Cardiovascular Function and Stress Response
The PVN plays a critical role in modulating cardiovascular function, blood volume
and blood osmolarity.1,11 In addition, studies have shown that PVN neurons are
essential in driving stress-induced sympathetic activation.3,7 In particular, the PVN
can strongly influence cardiovascular activity in response to stressful stimuli,
including increases in arterial pressure and heart rate.12,13 Meanwhile, inhibition of the
PVN in spontaneously hypertensive rats (SHR) and Dahl salt-sensitive hypertensive
rats triggers a reduction in arterial pressure.10
The effects of altering GABA and glutamate signaling in the PVN on normal
cardiovascular functioning have been demonstrated in a number of studies. Blocking
PVN neuronal activity using either glutamate receptor antagonists or GABA receptor
3

agonists abolishes stress-induced increases in HPA axis activity, heart rate and blood
pressure.3 However, a five-fold increase in muscimol (GABA agonist) in the PVN
reverses this inhibition.3 This may be due to the spreading of the drug, causing outside
GABA activation, which in turn inhibits GABA neurons projecting into the PVN.
These data support that the area surrounding the PVN is densely populated with
GABA neurons, which are vital in regulating the activity of PVN neurons.
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In

hypertensive animal models, NMDA-GABA signaling is shifted towards NMDAmediated excitation, which results in increased PVN activity, and sympathetic
activation.14,15 Studies have also demonstrated that in the PVN of SHR rats, GABA-A,
GABA-B receptors and GABA inputs are functionally altered to increase the basal
firing rate of PVN neurons.14 Moreover, in SHRs glutamate and GABA signaling is
shifted to induce PVN neuron hyperactivity.15 These changes in GABA and glutamate
signaling may be responsible for the development of hypertension.
Various regulatory pathways may elicit fine-tune changes in the glutamate and GABA
signaling in the PVN to adjust cardiovascular function. Angiotensin II (Ang II) and
BDNF are two significant mediators that can induce these changes, as detailed below.

1.4 Angiotensin II
Ang II’s role in cardiovascular function is well understood in the periphery. It is one
of the active hormones of the renin-angiotensin system (RAS). In this system, renin
cleaves angiotensinogen to form angiotensin I, which is converted to Ang II by
angiotensin-converting enzyme.16 Ang II drives excitatory cardiovascular responses
induced by stress, such as increases in blood pressure and vascular resistance. 12,13,16–18
The main receptor subtype mediating Ang II’s effects, the angiotensin type 1 receptor
(AT1-R), is a G protein coupled receptor that can have a wide range of effects
depending on the downstream pathway it is linked to and the tissue the signaling
4

occurs in.19 There is also a distinct RAS in the brain, which is independent from the
systemic RAS.20 The brain RAS includes all of the necessary molecules required for
the production and degradation of Ang II.20 All the components of the brain RAS
have also been described in the PVN.18,21,22 However, the mechanism of Ang II’s
actions in the PVN are far less understood.12 There is well established data illustrating
that can Ang II act like a neurotransmitter in the control of sympathetic outflow and
cardiovascular changes in the PVN.18 For instance, Ang II exerts its cardiovascular
effects in the PVN through increased norepinephrine and glutamate levels, increased
AT1-R expression and decreased GABA neurotransmission.17 Moreover, blocking
AT1-R in the PVN has been shown to reduce stress-induced mean arterial pressure
increases typically seen in restraint tests.12 Other studies have demonstrated that Ang
II can alter currents through a variety of ion channels. For example, PVN neurons are
excited by Ang II through a mechanism involving activation of a mixed cation current,
suspected to be a transient receptor potential (TRP) channel.13 In addition, Ang II in
the hypothalamus and brainstem triggers the production of superoxide via NADPH
oxidase. The increase in superoxide inhibits delayed rectifier potassium currents,
which in turn activates PVN neurons.23

1.5 BDNF
BDNF is part of a larger family of neurotrophins, which are vital in the normal
development of the central nervous system. 24 Studies have shown that neurotrophins
contribute to a variety of neuronal functions such as cell survival and inhibition of
apoptosis, dendritic branching, axonal density, neurotransmitter release, synaptic
plasticity, learning and memory.24
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1.6 BDNF structure and expression
BDNF is synthesized as a proneurotrophin and is later cleaved to the mature 13kDa
neurotrophin.25,26 The structure of BDNF is similar to other neurotrophins, with
around 50% of the amino acids being identical to nerve growth factor (NGF),
neurotrophin-3 (NT-3) and neurotrophin-4/5 (NT-4/5).27 BDNF consists of a
covalently bonded homodimer built from 8 mRNAs transcribed from the BDNF gene
on chromosome 11 in rats.27 BDNF mRNA is mainly expressed in the brain at high
levels during development, which later decline with age.27 In neurons, BDNF is
expressed in an activity-dependent manner during postsynaptic depolarization and
calcium signaling.26,28 Thus, BDNF expression is regulated by the effects of
neurotransmitters on membrane potential and intracellular calcium. For example,
antagonizing glutamate receptors or activation of GABA-ergic neurons has been
shown to decrease BDNF mRNA expression, while agonists of AMPA receptors
increase BDNF levels in the hippocampus.27

1.7 BDNF in the PVN
BDNF plays important roles in several larger organism-level homeostatic processes,
which are largely regulated by the hypothalamus. BDNF has been shown to alter food
intake and body weight through increases in hypothalamic serotonergic signaling.29
Normal activation and functioning of the HPA axis also depends on BDNF
expression.30 BDNF induces expression of CRH in the PVN, while decreased BDNF
diminishes both CRH levels and normal HPA functioning.30,31 Increases in blood
pressure induced by stress have also been shown to be modulated by BDNF in the
PVN. Microinjection of BDNF in the PVN elicits increases in blood pressure, while
stress induced increases in blood pressure are reduced following BDNF receptor
blockade.32,33 Similarly, BDNF mRNA levels increase in the PVN following stimuli
6

that induce increases in blood pressure, such as hyperosmolarity, stress or
amphetamine administration.32–34

1.8 BDNF Signaling Pathways
BDNF’s high affinity receptor is the tropomyosin receptor kinase B (TrkB), which
comes in two isoforms: the full length glycoprotein receptor and the truncated form
that doesn’t have a tyrosine kinase domain.27 The affinity of BDNF to TrkB can be
modulated via interactions with the low affinity p75 receptor.24,27 Upon binding,
BDNF induces TrkB receptor dimerization and autophosphorylation of the
intracellular tyrosine residues within the intracellular kinase domain. 26 This triggers
three main signaling pathways: Ras-Raf-extracellular signal-regulated kinase (ERK),
phospholipase C and phosphatidylinositol 3 (PI-3) kinase cascades.35,36 These
pathways are predominantly responsible for the longer lasting effects of BDNF,
including neuronal differentiation and survival. However, TrkB signaling has also
been implicated in the generation of membrane currents.25,

31

Blum et al (2002)

demonstrated that BDNF could evoke membrane depolarization through activation of
Nav1.9.37 The activation of sodium channels and membrane depolarization may be
the underlying mechanism behind BDNF’s role in faster neuronal processes. 26,37
Another study found that BDNF-induced currents in neurons require TrkB receptor
activation, mobilization of calcium from intracellular stores via sarco/endoplasmic
reticulum Ca2+-ATPase (SERCA) and inositol triphosphate receptor (IP 3-R)
dependent mechanisms, as well as extracellular calcium influx. TRPC3 was found to
be the ion channel that drives Ca2+ influx in response to BDNF binding to TrkB in
hippocampal neurons. Moreover, BDNF increases TRPC3 surface density through PI3 kinase dependent TRCP3 trafficking to the membrane and surface expression. 38
This evidence points to the idea that BDNF requires TRPC3 for inducing changes in
7

membrane potential, calcium influx and vesicular transmitter release within the
hippocampus.26,38,39

1.9 Acute effects of BDNF signaling
The TrkB receptor is expressed on both pre- and postsynaptic neurons and therefore,
activity dependent release of BDNF can affect both neurons in the synapse.40 Unlike
BDNF’s slower effects on survival and differentiation, BDNF has been shown to play
a role in synaptic transmission that occurs over a period of seconds or minutes. 40
Studies have demonstrated that BDNF can enhance neurotransmitter release from
presynaptic terminals in a period of minutes, both in the neurons of the central
nervous system, as well as at neuromuscular junctions.40 Not only does BDNF play a
significant role in short-term processes at the presynaptic end, but also at the
postsynaptic terminal. There is evidence to suggest that long-term potentiation and
excitatory neurotransmission is regulated by the activation of postsynaptic terminals
by BDNF.40 Activation of postsynaptic TrkB receptors by BDNF depolarizes the
neurons presumably through opening of sodium channels and NMDA channels,
subsequently driving influx of calcium and thus increasing intracellular calcium levels.
This then promotes AMPA receptor opening and long-term potentiation in the
postsynaptic cell.40

1.10 Intersection of BDNF, Ang II and TRPC3 in the PVN
It has been postulated that BDNF increases blood pressure within the PVN by
interacting with Ang II signaling. Both pathways are triggered by stress and exert
similar effects on the cardiovascular system in response.

32

Current evidence also

demonstrates that blocking the Ang II/AT1-R axis partially diminishes BDNFinduced increases in blood pressure by preventing TrkB receptor activation.32,33 This
suggests that TrkB and AT1-R rely on each other for cross-activation. Similarly, there
8

is evidence that in the periphery, AT1-R signaling transactivates other tyrosine kinase
pathways through downstream effects of G protein coupled receptor activation.19 Vice
versa, BDNF overexpression in the PVN increases AT1-R expression, while BDNF
antagonism has been found to reduce Ang II’s effects on sympatho-excitation.33,41
Since BDNF’s effects seem to involve activation of TRPC3, it is interesting that in the
PVN, Ang II induces a transient inward current, similar to those produced by TRP
channels.13 These same currents were also observed in Chinese hamster ovary cells
that expressed TRPC3 and AT1-R when treated with Ang II.13,42 Moreover, Ang II
induced inward currents in the PVN are blocked during application of a nonselective
cation channel blocker, which suggests that these effects may be mediated by a TRP
channel.13 In addition, TRPC3 is required to produce cardiac hypertrophy induced by
Ang II, which occurs through the PLC-mediated production of diacylglycerol (DAG)
downstream from AT1-R.43 All of this evidence points to an interaction between TrkB,
AT1-R and TRPC3. Perhaps AT1-R signaling activates TrkB, which in turn induces a
change in membrane potential through TRPC3. An alternative mechanism could be
that AT1-R activation induces neuronal activity, which in turn releases BDNF and
subsequently drives an inward current via TrkB and TRPC3. Depolarizing currents
through TRPC3 may subsequently increase neuronal firing and may be a potential
mechanism by which BDNF activates PVN neurons. However, currently there are no
studies investigating TRPC3 as a potential mediator of the hypothalamic effects
induced by BDNF and Ang II. (Fig. 1)
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Legend:
•
•
•
•
•
•
•
•

P= phosphorylated
PLC= phospholipase C
PIP2= Phosphatidylinositol 4,5-bisphosphate
IP3= Inositol triphosphate
DAG= Diacylglycerol
PI-3 Kinase= Phosphoinositide 3-kinase
SERCA=Sarco/endoplasmic reticulum Ca²⁺ATPase
IP3R= Inositol trisphosphate receptor

Figure 1: Ang II and TrkB receptor interaction triggers PI-3 kinase dependent TRPC3
trafficking to the membrane and influx of calcium. Autophosphorylation of the TrkB
receptor activates PLC and induces IP3 production though PIP2, which drives calcium
release from intracellular calcium stores via IP 3R. Intracellular calcium stores are
maintained through SERCA. (Adapted from Amaral et al, 2007)
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1.11 Methods of Studying Neuronal Activity in the PVN
Methods to examine neuronal activity have been rapidly developing, allowing
researchers to gain insight into real-time changes within a neural network. The most
common techniques include patch-clamp, large-scale brain imaging and voltagesensitive dye-based imaging.44 Often PVN neuronal activity is studied using patchclamp and dye-based imaging in brain slices.
Patch-clamp is used to study single cells at a time, particularly to examine individual
ion channel function. This technique provides incredible detail on specific cells, but is
limited to studying single neurons at a given time, and therefore cannot be used to
effectively examine complete neural networks. However it has still been a valuable
technique used to study PVN neuronal activity. For instance, Li & Pan (2005)
demonstrated the effects of Ang II on firing rate of PVN neurons using whole cell
patch-clamp recordings. From these recordings, they determined that Ang II increases
firing of RVLM-projecting PVN neurons through the attenuation of GABAergic
inputs.45
Dye-based imaging can be conducted with either voltage-sensitive dyes or calciumsensitive dyes. Dyes are very useful in studying layers of the same cell type, though
this becomes problematic when studying tissues with diverse cell types. Moreover,
some cells do not readily take up dyes and therefore would be omitted in the imaging
process. Some dyes, like calcium green-1 or Oregon Green Bapta-1, require
puncturing the cell of interest to load the indicator dye, which can compromise the
cell.44,46,47 The brain can also be directly injected with voltage-sensitive dyes and
neurons can be recorded through an anesthetized animal’s skull.44 Recordings with
this technique are often restricted to a depth of around 200μm, and hence can only be
11

used study cortical activity.44 Moreover, this technique is difficult to apply to a deeper
brain region like the PVN.

1.12 The Use of GECIs to Explore Calcium Signaling Patterns
The development of genetically encoded calcium indicators (GECIs) has allowed
researchers to explore calcium signaling patterns in neurons more in-depth than ever
before. These indicators are made up of fluorescent proteins sensitive to changes in
intracellular calcium concentration, which are indicative of changes in electrical
activity within a neuron.48 Due to the diverse application of GECIs, including viral
injections, transgenic animals and whole brain imaging, this method has been
increasing in popularity, as it enables researchers to gain a wider view of calcium
activity, while being deeper in tissue.48 Studies have shown that calcium transients
can be directly linked to action potentials, as represented by increases in fluorescence.
As action potentials are extremely fast, in the scale of milliseconds, increases in
calcium levels can last two times longer than the action potential itself. 48 Hence, the
choice of indicator is important as some GECIs have different kinetics. For example,
the GCaMP6s (slow) has a peak in fluorescence at 179 ms and a 550 ms decay time
following a single action potential, compared to GCaMP6f (fast) with a peak within
45 ms and decay time of 142ms.48 It is also significant to note that fluorescence levels
primarily change in response to suprathreshold depolarizations, with minimal
subthreshold changes. This method has also been proven to be effective in detecting
changes in fast-spiking cells, though individual spikes cannot always be resolved.
Increases or decreases in calcium levels may represent overall changes in firing rate.48
This technique allows for recordings of larger populations of neurons over longer
time periods, while also being able to examine smaller structures like dendrites or
axons that are inaccessible with traditional electrophysiology. 49,50 There is also less
12

selection bias when using GECIs, as a large population of neurons can be studied,
rather than selecting a single neuron to study with patch-clamp. The use of GECIs has
allowed researchers to gain insight into spatiotemporal activity within a population of
neurons, while minimizing damage to the tissue compared to traditional electrical
recordings.51 This technique also allows specific cell types to be labeled using viral
vectors and selective promoters.50
Though GECIs have revolutionized methods for tracking neuronal activity, there are
some limitations to consider. There is firstly some variability of calcium signal from
the same cell type, which can possibly be attributed to differences in GECI
expression.48 One must also consider issues with photon detection, random emission
and photo-bleaching from optical imaging that may impact receiving accurate
results.50
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1.13 Aims of Thesis
The following aims were developed to investigate neuronal activity within the PVN
and explore the complex interaction between BDNF and Ang II. The previous work
of the Erdos lab has demonstrated the important role of BDNF in sympathetic activity
and cardiovascular regulation via modulation of the Ang II/AT1-R system.32,33 This
work uncovered the potential intersection between BDNF and Ang II that warranted
further exploration into understanding the molecular basis of BDNF and Ang II crossactivation within the PVN.
Aim 1: Develop techniques to assess PVN neuronal activity using a GCaMP Ca2+
sensor and characterize intracellular Ca2+ events under baseline conditions.
1) We have optimized procedures to inject a viral vector expressing GCaMP6f Ca2+
sensor in the PVN. 2) We have optimized slicing protocols to improve Ca2+ detection
and viability of PVN neurons. 3) By blockade of sodium channels, L-type calcium
channels, AMPA and NMDA and administration of GABA we have inhibited PVN
neurons to characterize intracellular Ca2+ responses, and 4) developed a process to
analyze calcium signals
Aim 2: Investigate the effects of Ang II and BDNF-TrkB receptor activation on
PVN neuronal activity and elucidate the role of TRPC3 ion channels in these
responses. BDNF and Ang II have been shown to interact with each other,
particularly in the regulation of blood pressure, via AT1-R and TrkB cross-activation.
We investigated this relationship by 1) observing and quantifying changes in calcium
signals in response to the application of Ang II, 7,8-dihydroxyflavone hydrate (a TrkB
agonist known as DHF), GSK 1702934A (a TRPC3 agonist) and Pyr3 (a TRPC3
inhibitor).
14

2. Materials and Methods
All animal housing, handling, surgical and experimental procedures were conducted
within an Association for the Assessment and Accreditation of Laboratory Care
International-accredited animal care facility at the University of Vermont, in
accordance with the U.S.A. Public Health Service Policy on Humane Care and Use of
Laboratory Animals and the National Institutes of Health’s Guide for the Care and
Use of Laboratory Animals. Experiments were performed in male Sprague-Dawley
(SD) rats obtained from Charles River (Saint-Constant, QC, Canada) at 3 weeks of
age. Rats were housed individually with a 12-hour light/dark cycle (lights on at 6:00
am), with free access to food (standard chow) and water. Surgeries were performed
under continuous isoflurane anesthesia (5% induction; 2–3% maintenance) delivered
in oxygen. Depth of anesthesia was assured by close monitoring of blood pressure,
heart rate, and lack of eye blink and hind paw pinch reflex responses. Survival
surgeries were conducted using aseptic technique and carprofen (5 mg/kg/day s.c.)
was administered for post-surgical analgesia at the beginning of surgery and for two
days during post-surgical recovery. All experimental procedures were approved by
the Institutional Animal Care and Use Committee at the University of Vermont.

2.1 Experimental design and surgical procedures
Viral Vector injections
The purpose of these experiments was to study calcium signaling in order to
characterize neuronal activity in the PVN and elucidate TRPC3 ion channel mediated
mechanisms by which BDNF and Ang II activate these neurons. Under isoflurane
anesthesia, rats were secured in a stereotaxic frame and viral vector stock solutions
were injected bilaterally into the PVN using pipettes pulled from thin walled
borosilicate glass capillary tubes (OD, 1 mm; ID, 0.58 mm; tip diameters, ~25 um) at
the following stereotactic coordinates: 0.5mm posterior, -1.7mm lateral from bregma
15

and 7.3mm ventral from the brain surface at a 10 degree tilt towards the mid-line.
Virus stocks of AAV2-CaMP6f (1012 viral particles/ml; 200 nl/side) were injected
over 5 minutes using a pneumatic pico pump. The pipette was left in place for an
additional 3 minutes. Following surgery, rats were left to recover for a week.
aCSF Preparation
Three buffers were made prior to the brain extraction: a recording solution, a recovery
solution and a slicing solution. Once solutions were prepared, they were bubbled with
95% O2/5% CO2 for 15 minutes and adjusted to a pH of 7.3-7.4. The slicing solution
contained (in mM) 126.8 NaCl, 24.1 NaHCO3, 3.5 KCl, 1.3 NaH2PO4, 10 glucose, 10
MgCl and 0.5 CaCl2 in 1 liter of nanopure water. The recording solution contained (in
mM) 126.8 NaCl, 24.1 NaHCO3, 3.5 KCl, 1.3 NaH2PO4, 10 glucose, 0.5 MgCl and 1
CaCl2 in 0.5 liters of nanopure water. The recovery solution contained (in mM) 93
NMDG, 2.5 KCl, 1.2 NaH2PO4, 30 NaHCO3, 20 HEPES, 25 glucose, 5 sodium
ascorbate, 2 thiourea, 3 sodium pyruvate, 12 N-acetyl-L-cysteine, 10 MgSO4 and 0.5
CaCl2 in 0.5 liters of nanopure water.
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Recovery Buffer 0.5L
NMDG
KCl
NaH2PO4
NaHCO3
HEPES
Glucose
sodium ascorbate
thiourea
sodium pyruvate
N-acetyl-L-cysteine
MgSO4-2.5ml from 2M stock
CaCl2-0.25ml from 1M stock

mM
93
2.5
1.2
30
20
25
5
2
3
12
10
0.5

g
9.08
0.09
0.09
84
2.38
2.25
0.5
0.08
0.17
0.98

Slicing Solution
NaCl
NaHCO3
KCl
NaH2PO4
Glucose
MgCl- 10ml from 1M stock
CaCl2-5ml from 1M stock

mM
126.8
24.1
3.5
1.3
10
10
0.5

g
7.4
2.02
0.26
0.204
1.8

Recording Solution 0.5L
NaCl
NaHCO3
KCl
NaH2PO4
Glucose
MgCl-0.5ml from 1M stock
CaCl2-1ml from 1M stock

mM
126.8
24.1
3.5
1.3
10
0.5
1

g
3.7
1.01
0.13
0.102
0.9

Table 1: List of slicing, recovery and recording solutions used to generate PVN slices
and record from them.
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Generating PVN brain slices
Using 5% isoflourane, rats were deeply anesthetized and decapitated. The brain was
quickly removed and put in a brain block submerged in ice-cold slicing solution. We
cut a coronal slab extending rostral to the anterior cerebral artery and caudal to the
posterior cerebral artery. This brain slab was then placed in a petri dish containing
slicing solution on ice. The cortex was cut off leaving just the medial section of the
brain. The brain was then quickly glued to the stage of the vibratome and immersed in
ice-cold slicing solution bubbled with 95% O2/5% CO2. 400μm slices were cut and
immediately transferred into wells in a container filled with the recovery buffer at
38˚C bubbled with 95% O2/5% CO2. After 15 minutes, slices were transferred from
the recovery buffer to the slicing solution at room temperature bubbled with 95%
O2/5% CO2. Slices were stored in this solution until they were mounted on the
microscope.
Recording chamber and temperature control
To record Ca2+ events from PVN neurons, brain slices were placed in a shallow
recording chamber (RC-22, Warner Instruments) containing recording solution
bubbled with 95% O2/5% CO2. The recording solution was stored in a reservoir and
was gravity fed into the recording chamber and then returned to the reservoir with a
peristaltic pump. The temperature of the solution was maintained at 35˚C using an inline heater and monitored with a temperature probe in the recording chamber
throughout the experiment.
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2.2 Recording of Ca2+ signals
An individual slice was placed in the recording chamber and a region of the PVN
showing viral vector expression was excited at 900nm and visualized with a Zeiss
LSM7 Multiphoton microscope with a 20X/1.0NA objective. The output at the
objective was 3-9 microWatts, while the sampling interval was 391.1 ms. We used a
gain of 700, laser power of 7-11% of max output and a zoom of 1.2. The dimensions
of the view area were 250μm by 250μm. The slice was left in the chamber for 20
minutes superfused with the recording solution at 38˚C before the first recording.
Experiments were conducted following one of these protocols:
A. Agonist experiment: a 5-minute control time series was recorded, followed
by a 2-minute inactive period, which was used to prepare the agonists and
pipette them into the circulating system. This was followed by a 5-minute
time series to capture the immediate effect of the agonist. 10 minutes after
the initial application of the agonist, another 3-minute time series was
taken to record any long-term effects. At the end of the experiment, KCl
(20mM final concentration) was added to the reservoir to detect maximum
fluorescent intensity in depolarized neurons and verify the viability of the
neurons. Finally, a z-stack of a ~100μm deep section of the slice was
recorded for future structural analysis of PVN neurons and their processes.
The 2-minute interval between recordings was used consistently in all
experiments, which gave us time to prepare drugs and pipette them in
between recordings
B. Antagonist experiment: a 5-minute control time series was recorded, and
2-minutes later an antagonist was pipetted into the reservoir. After 10
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minutes had passed from initial application of the antagonist, a 5-minute
recording was taken. The protocol then proceeded the same way as
outlined in the agonist condition.
C. Time controls:
a. Time controls were conducted according to the same protocols
outlined above, but without applying any drugs

Drug preparations

Drug
AP-5
CNQX
TTX
GABA
Ang II
DHF
KCl
Biciculline
Nifedipine
GSK
Pyr3

Solvent
aCSF
aCSF
water
PBS
PBS
DMSO
(<1%)
water
DMSO
(<1%)
DMSO
(<1%)
DMSO
(<1%)
DMSO
(<1%)

Concentration
50 μM
10 μM
1 μM
40 μM
2 μM
1 μM
20 mM
50 μM
30 μM
Low dose: 6 μM; High dose: 24

μM
30 μM

Table 2: Summary of drugs used in experiments, including the experimental
concentrations and solvent used to prepare the solutions
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Calcium signal analysis
Analysis was conducted using the freely available software Fiji (https://fiji.sc/) and an
in-house analysis software (Volumetry) developed by Dr. Grant Hennig at the
University of Vermont.
Files were first converted from .lsm to .tif files in Fiji. The tif file to be analyzed was
then imported into Volumetry. Images were “decombed,” which eliminated any
artifacts caused by the scanning of the two-photon microscope back and forth across
the tissue.

Figure 2A & B: illustrates the effect of the “decombing” function on a single
neuron. A: cell body before the decombing function. B: the same cell body
after decombing.

For each pixel at each specific time point, its standard deviation was calculated based
on the pixel’s intensity in the previous 4 and subsequent 4 frames. This step was
repeated for every pixel at every time point, which resulted in a standard deviation
image for each specific time point of the time series. Next, Volumetry compared the
intensity of a single pixel at a certain time, to the intensity of the same pixel in the
next frame. If the intensity difference between the two pixels was greater than 5.2
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times the standard deviation (calculated as described above) then this pixel was
considered “active” during the recording. The 5.2 value was determined through trial
and error while optimizing sensitivity and specificity. This value was then used for
every recording to not bias our analysis. Next, a particle filter was applied, which
removed pixels smaller than a specified size. Once a specific particle filter was found
to be appropriate to detect PVN neurons, this same filter size was applied to all of the
files for a single slice. The file was then converted into a single image by projecting
of all the particles from each individual frame onto a 2D image, which displayed all
of the areas of activity, known as the “mask.”

Figure 3 A & B: shows how the mask is overlaid onto the “decombed” file to
identify ROIs in the recording. A: the mask file showing all the active sites
determined with the parameters described above. B: shows which areas are
considered ROIs using the mask.

The mask file was overlaid onto the original “decombed” file and regions of interest
(ROI) were identified. Once we identified our active sites, we calculated the average
intensity of a single ROI over a time period, and generated traces to represent these
22

intensity changes over time.
An experiment typically consisted of 5 to 6 recordings during which the neurons were
treated with specific pharmacological agents (Table 2). To compare recordings i.e. to
assess the effect of pharmacological treatment, we determined three main parameters.
“Active sites” corresponded to the number ROIs generated using the algorithms
described above. “Average Intensity” was calculated as the mean of absolute ROI
intensity over time across all ROIs. The “Average Intensity” was then multiplied by
the number of active sites to create a parameter named “Cumulative Intensity.” In
drug conditions, the first 20 seconds were not included in the averages, so as to only
capture the effect of the drug after it had reached the recording chamber.
Graphs were generated using GraphPad Prism 8 to show the mean and standard error
of the mean (SEM). Statistical significance was determined using paired t-tests
between conditions.
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3. Results
3.1 Baseline Neuronal Ca2+ events
In our preparation, neurons displayed “spontaneous” activity even without stimulation
by pharmacological agents. There were diverse spontaneous behaviors demonstrated
by neurons. Some neurons showed regular, high intensity fluctuations in intracellular
calcium, others had low intensity minimal changes and some displayed random
intensity changes (Fig. 4A-D).

Figure 4 A-D: spontaneous changes in intensity of four ROIs through time. A:
shows highly regular fluctuations both in frequency and intensity. B: low
amplitude random fluctuations in intracellular calcium. C: low amplitude random
fluctuations interrupted by intermittent marked decreases in intensity. D: random
changes in intracellular calcium superimposed on larger and slower “waves” of
fluorescent intensity.
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3.2 Time Control Experiments
Our chosen activity parameters (“Average intensity,” “Active sites” and “Cumulative
Intensity”) may be susceptible to changes in both cell viability and Ca2+ indicator
fluorescence. Prolonged exposure to laser has been shown to impair cell viability and
cause photo-bleaching. To determine whether these factors played a role in our
protocol, and thus affected our interpretation of the data, we conducted time control
experiments using the same protocol used for drug applications. We also conducted
additional time control experiments where an initial recording was taken followed by
a second recording 40 minutes later to test the effect of time without repeated
exposure to laser. In the time control condition that emulated agonist experiments,
there were no significant changes in the number of active sites, average intensity, or
cumulative intensity during the first three recordings (control, 5 min and 10 min, Fig.
5A). In the time controls that were modeled after antagonist experiments, there were
also no significant changes in any of our parameters during the first three recordings
(control, 10 min and 15 min Fig. 5B). There were no significant changes in average
intensity and cumulative intensity in the time controls where a control was recorded
followed by a second recording 40 minutes later. However, there was a significant
decrease in the number of active sites after 40 minutes (Fig. 5C). These results
demonstrated that neurons in our preparation displayed “spontaneous” activity and
were not affected by laser-induced photo-bleaching or neurotoxicity during the time
period used for our agonist and antagonist experiments.
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Figure 5 A-C: number of active sites, average intensity and cumulative intensity in
three conditions of time controls. A: No significant changes were observed during
time-control protocols identical to those used for agonist experiments (N=7). B: time
controls modeled after antagonist experiments, which also show no significant
changes in our parameters (N=2). C: time controls where the slice was recorded at
the start and end of the experiment (40 mins). There were no significant changes
aside from a decrease in the number of active sites after 40 minutes (p=0.033; N=2).
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3.3 Effects of Inhibitors (GABA, Nifedipine, TTX, Bicuculline+AP-5+CNQX)
To characterize PVN neuronal activity and intracellular Ca2+ events, as detected by
changes in GCaMP6f fluorescent intensity, we manipulated GABA-mediated
inhibition, glutamate-mediated excitation, sodium channel function, and voltagedependent Ca2+ channel function.
To verify that the observed neuronal Ca2+ events were dependent on neuronal firing
and influx of extracellular Ca2+ through voltage gated Ca2+ channels, we used the
sodium channel blocker tetrodotoxin (TTX, 1μM) and the L-type calcium channel
blocker nifedipine (30μM). Neuronal activity (action potential firing) requires Na+
influx through Na+ ion channels. Membrane depolarization in turn induces an increase
in intracellular calcium mediated by voltage-gated calcium channels.48 TTX tended to
decrease the number of active sites and cumulative intensity compared to control.
However, average intensity of the sites that remained active after TTX were not
significantly different from the control, indicating that TTX application failed to
inhibit Ca2+ events in a small population of PVN neurons (Fig. 6A). In contrast,
nifedipine completely abolished all neuronal activity and Ca2+ events so that active
sites were no longer detected (Fig. 6B).
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Figure 6 A&B: the effect of TTX and nifedipine on number of active sites,
average intensity and cumulative intensity. A: TTX tended to decrease the number
of active sites (p=0.16), as well as cumulative intensity (p=0.19), though changes
in average intensity of the remaining active sites were not significant (N=3). B:
nifedipine eliminated all neuronal activity (N=3).
Next, we tested GABA-mediated inhibition of PVN neuronal activity, and found that
GABA (40μM) application significantly decreased the number of active sites and
cumulative intensity, indicating that most neurons in the PVN are inhibited by GABA.
The average intensity of the remaining active sites did not change significantly, which
suggests a small population of PVN neurons remained unaffected by GABA treatment
(Fig. 7A).
It was unclear whether synaptic connections between the peri-PVN regions and PVN
neurons in our brain slices remained intact after vibratome slicing. This potentially
complicated our interpretation of the data, as drugs superfused onto our slices may
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have affected both the PVN neurons and peri-PVN inhibitory or excitatory neurons
synapsing onto PVN neurons. We used a “cocktail” of biciculline (GABAA antagonist,
50μM), AP-5 (NMDA receptor antagonist, 50μM) and CNQX (AMPA receptor
antagonist, 10μM) to inhibit any peri-PVN synaptic connectivity and reveal the
intrinsic activity of PVN neurons without the influence of any other input.
Interestingly, this combination tended to decrease the number of active sites and the
cumulative intensity compared to control. However, the average intensity of cells that
remained active was unchanged from the control (Fig. 7B).

Figure 7A&B: the effects of GABA and an inhibitory cocktail of bicuculline, AP-5
and CNQX on number of active sites, average intensity and cumulative intensity. A:
GABA significantly decreased the number of active sites from control (p=0.0078), as
well as the cumulative intensity (p=0.038). There was no significant change in the
average intensity of active sites that remained following GABA application (N=8). B:
The inhibitory cocktail tended to decrease both the number of active sites (p=0.13) and
the cumulative intensity compared to control (p= 0.1528), while the average intensity
of the remaining active sites was unchanged (N=3).
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3.4 Effects of Ang II and DHF
We and others have previously shown that injection of BDNF and Ang II into the
PVN induces an acute increase in systemic blood pressure, suggesting direct
excitatory effects of these substances on PVN neuronal activity.13,32 To test this
hypothesis, we applied Ang II (2μM) and the TrkB receptor agonist DHF (7,8dihydroxyflavone hydrate, 1μM) alone, as well as in combination to PVN slices.
Surprisingly, Ang II had no effect after 7 minutes, but did tend to decrease both the
number of active sites and cumulative intensity 10 minutes after application. There
were no significant changes in the average intensity of active sites compared to
control (Fig 8A).
Because PVN neurons are thought to be under significant GABA inhibition due to
peri-PVN GABA-ergic inputs, we postulated that we would potentially see an
excitatory effect of Ang II if the slices were pre-treated with GABA. This was an
attempt to mimic the physiological environment that PVN neurons usually exist in.
When slices were pre-treated with GABA, Ang II tended to increase the number of
active sites and cumulative intensity 7 minutes after application (p=0.30; p=0.0865).
However, there were no significant changes in the average intensity of the active sites
(Fig 8B).
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Figure 8A & B: the effect of Ang II with and without the pre-treatment of GABA on
number of active sites, average intensity and cumulative intensity. A: Ang II tended
to decrease the number of active sites after 10 minutes (p=0.14) but did not
significantly affect any of our measured parameters 7 minutes after application
(N=7). B: when slices were pre-treated with GABA, Ang II tended to increase the
number of active sites (p=0.30) and cumulative intensity after 7 minutes (p=0.0865).
There were no significant changes in average intensity (N=3).

Next, we examined the effects of DHF alone (1μM), and the combination of Ang II
(2μM) and DHF. 7 minutes following DHF application, the number of active sites
significantly decreased. DHF also tended to decrease the number of active sites after
10 minutes, while the average intensity of active sites tended to increase 7 minutes
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after DHF. The cumulative intensity also tended to decrease 10 minutes after DHF
application (Fig 9A).
Ang II and DHF in combination did not have any significant changes on the average
intensity of active sites. However, this combination tended to decrease the number of
active sites after 10 minutes. Similarly, 7 and 10 minutes following Ang II and DHF
application, the cumulative intensity tended to decrease (Fig 9B).

Figure 9 A&B: the effect of DHF and DHF with Ang II on the number of active sites,
average intensity and cumulative intensity. A: DHF significantly decreased the number of
active sites compared to control 7 minutes after application (p=0.020). DHF tended to
decrease the number of active sites after 10 minutes (p=0.0564). Average intensity tended
to increase 7 minutes after DHF (p=0.062). Cumulative intensity tended to decrease after
10 minutes (p= 0.0685; N=6). B: Ang II & DHF tended to decrease the number of active
sites after 10 minutes (p=0.051), as well as the cumulative intensity after 7 minutes and 10
minutes (p=0.073; p=0.095). There were no changes to the average intensity (N=7).
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3.5 Effects of GSK and Pyr3
Because Ang II and BDNF induced effects are potentially interdependent and may
involve the transient receptor potential channel TRPC3, we used a TRPC3 agonist,
GSK 1702934A, at two different concentrations (low dose 6μM, high dose 24 μM)
and Pyr3, a TRPC3 inhibitor (30uM).13,19,32,33,41 GSK activates TRPC3 and TRPC6
currents with an EC50 of 0.08mM and 0.44mM respectively.52
There was a significant decrease in the number of active sites 10 minutes after the
application of a low dose of GSK, which only activates TRPC3. The average intensity
of the active sites tended to increase after 10 minutes, while the cumulative intensity
tended to decrease 10 minutes after a low dose of GSK compared to the control (Fig
10A).

In addition, 10 minutes after a high dose of GSK, we noted a significant decrease in
the number of active sites compared to the control. On the other hand, the average
intensity of active sites tended to increase compared to control (Fig 10B).

When Pyr3, an inhibitor of TRPC3, was administered, there were no significant
changes in the number of actives sites, average intensity and cumulative intensity
compared to the control (Fig 10C).
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Figure 10 A-C: effects of a low dose of GSK, high dose of GSK and Pyr3 on the
number of active sites, average intensity and cumulative intensity. A: There was a
significant decrease in the number of active sites 10 minutes after a low dose of GSK
was applied (p=0.007). The average intensity tended to increase after 10 minutes
(p=0.293; N=3). B: a significant decrease in number of active sites was observed 10
minutes after a high dose of GSK (p=0.025). The average intensity tended to
increase 7 minutes and 10 minutes after GSK application (p= 0.122; p=0.11). There
were no significant changes noted in cumulative intensity (N=3). C: There were no
changes in thr number of active sites, average intensity and cumulative intensity
between the control and Pyr3 condition (N=6).
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4. Discussion
This study demonstrates the potential of using GCaMP Ca2+ indicators to analyze
neuronal networks and individual neuronal activities in the PVN. We successfully
demonstrated that neuronal activity could be inhibited with known inhibitory drugs
such as TTX (voltage-gated sodium channel inhibitor), nifedipine (L-type calcium
channel inhibitor) and GABA. On the contrary, we were unable to demonstrate
significant actions of Ang II, DHF or GSK on neuronal activity. These findings were
unexpected, as previous studies have found that both Ang II and BDNF-TrkB
activation have excitatory effects in neurons of the PVN.13,32,35,39,45 Studies have also
demonstrated that activation of TRPC3 can both drive influx of Ca2+ into the cell and
induce the opening of L-type Ca2+ channels.35,43

4.1 Calcium Imaging to Assess PVN Neuronal Activity
Here, for the first time, we successfully demonstrate the use of calcium imaging to
study complete neuronal networks in the PVN. The success of this technique relied on
several key components: GCaMP6f transduction, the brain slice recovery protocol and
using the multi-photon microscope to access deeper layers of tissue. In our
preparation, we successfully transduced GCamP6f into neurons of the PVN using a
viral vector and a general promoter. As a result, we were able to selectively study
neurons in the PVN. In future studies, a more selective promoter could be used to
target specific groups of neurons. In the process of developing a reliable protocol, we
also found that using a recovery buffer following slicing was key in maintaining slice
viability. Other studies have shown that there are a few vital components of this
recovery solution that allow for healthy brain slices to be prepared. 53,54 Reducing
sodium ions in the recovery solution is critical to minimize neuronal swelling and
potential pyknosis. Sodium ions in the other solutions are replaced with methylated
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organic cations, such as N-methyl-D-glucamine (NMDG), which effectively
decreases the permeability of sodium channels in neuronal membranes during sudden
changes in temperature. Finally, when slices are incubated following slicing they tend
to suffer from edema, which can be reduced by including HEPES in the solution.53,54
Though there are many variations of this recovery buffer, these three components
allow for the preservation of healthy neurons in a slicing preparation. The multiphoton microscope was another critical part of our protocol, which enabled us to
resolve rapid intracellular Ca2+ dynamics, image deeper in the tissue, all while
reducing photo-bleaching compared to conventional confocal microscopes.55 Initially,
we had tried using a spinning disk confocal microscope, which is typically used with
thinner tissue samples.56 However, we were unable to observe any activity with this
particular microscope. This may have been because we were only able to visualize
superficial neurons, which could have been damaged or lost their synaptic
connections in the slicing process. In comparison to patch-clamp studies in which
electrodes can only access superficial neurons, our protocol using the multi-photon
microscope allowed us to study neurons away from the cut surface.

4.2 Time Control Experiments
The time control experiments we conducted successfully demonstrated that our
protocol maintains cell viability throughout experiments and that photo-bleaching is
minimized. We focused our analysis on the immediate response of neurons to drugs,
as well as 10 minutes after application, though we did typically add other drugs to the
same slice past the 10 minute mark. However, according to our time controls we
tended to lose signal if the experiment lasted 40 minutes as indicated by Fig.4C, and
thus we limited our experiments single drug effects.
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4.3 Heterogeneity of Ca2+ traces
Throughout our experiments, we were able to get a glimpse into the heterogeneity of
Ca2+ trace characteristics of PVN neurons. We saw a diverse range of behaviors,
where some neurons were active and fired continuously or intermittently, while others
were inactive or fired in a rhythmic pattern (Fig 11). Without doing any analysis of all
the traces from a slice, it appears that Ang II may have an effect on firing patterns that
were otherwise obscured in our whole slice-based analysis (Fig 11). If we had used a
patch clamp protocol, this heterogeneity of PVN neurons would not have been easily
identified, as only single neurons can be recorded at a time with this technique.
Moreover, if the voltage were clamped, the intrinsic “spontaneous” activity pattern of
PVN neurons would not be visible. Because we were studying complete networks of
neurons, we did not classify individual neuron behaviors into groups. Our laboratory
has started to develop software in order to re-analyze the data on an individual neuron
basis. Data collected during these experiments will hopefully contribute to this future
endeavor in the Erdos lab.
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Figure 11: shows the diversity of neuron traces in a slice before and after the
application of Ang II. In some cases, Ang II appears to affect frequency of neuronal
firing or the pattern of Ca2+ traces without affecting the average intensity.

4.4 Inhibitor Experiments
TTX
Voltage gated sodium channels (Nav channels), as their name suggests, are opened
based on changes in membrane voltage and are responsible for generating and
propagating action potentials in neurons. These sodium channels are typically
classified based on their sensitivity to TTX. Three types of TTX sensitive Na v
channels have been identified in the PVN: Nav1.1, Nav1.2 and Nav1.3.1 A significant
study by Blum et al (2002) demonstrated that BDNF can induce membrane excitation
through Nav1.9, which not only illustrates BDNF’s neurotransmitter-like actions but
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also shows that sodium channels can be ligand-gated.26 This particular Nav subtype is
TTX-insensitive. Thus far, no studies have examined the presence and role of Nav1.9
in the PVN.1 It also has been established that BDNF in the PVN inducse sympathoexcitation, though these underlying mechanisms are still unclear33,57. Nav1.9 is a
viable candidate through which BDNF may exert its effects in the PVN. Our results
demonstrated that TTX tended to decrease both the number of active sites and
cumulative intensity, but the average intensity of active sites that remained was
unchanged from the control. This indicates that there are potentially TTX-insensitive
neuron populations in the PVN that stayed active in the presence of TTX. It is
possible that Nav1.9 may be responsible for the activity that we observed. Further
studies are needed to confirm both the presence of Nav1.9 and its role in BDNFevoked depolarizations in the PVN.
Nifedipine
Calcium plays a significant role in neuron excitability and action potential
propagation, whereby Ca2+ ions trigger synaptic vesicle release.58,59 L-type Ca2+
channels are voltage gated channels, activated through membrane depolarization, and
allow for influx of Ca2+ into the neuron.1 This type of channel is highly selective for
Ca2+ ions and is found throughout the PVN.1 Calcium can also be released from
intracellular stores, like the endoplasmic reticulum (ER) or mitochondria, following
activation of excitatory synapses.60 Activation of ryanodine or IP3 receptors triggers
release of calcium from the ER, following influx of Ca2+ through voltage dependent
calcium channels.60 Our results demonstrated that blockade of L-type calcium
channels with nifedipine completely eliminated all the active sites that had been
initially present in the control. Paired with the results from TTX, as described above,
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we can determine that any calcium activity we observed in the control must have been
due to action potentials and voltage dependent Ca2+ entry.

GABA
The firing activity of the PVN is predominantly regulated by GABAergic inputs, and
to a lesser degree, glutamatergic inputs.3,61 These peri-PVN presynaptic GABA
neurons are believed to be located in a ring around the PVN. 3 With this in mind, we
anticipated that GABA application would result in a decreased number of active sites,
which is indeed what our results reflected. This illustrated the general sensitivity and
responsiveness of PVN neurons to GABA. However, the active sites that did remain
following GABA treatment did not change in average intensity. Interestingly, it seems
that some neurons in the PVN may be unresponsive to GABA.
Inhibitory Cocktail Experiments
Our interpretation of the experiments in which we superfused drugs onto whole slices
is complicated by synaptic connections between PVN and peri-PVN neurons. A drug
could have affected the PVN, peri-PVN or both neuron populations, though this
would be indistinguishable to us. Hence, we used an inhibitory cocktail of CNQX,
AP-5 and bicuculline in an attempt to block any GABA-ergic or glutamatergic
synaptic connectivity and distinguish intrinsic activity of PVN neurons. We found
that this cocktail tended to decrease both the number of active sites and cumulative
intensity, while average intensity remained unchanged. These results suggest the
presence of neuronal network oscillations between glutamatergic and GABA-ergic
neurons, which have not been described in the PVN thus far.
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4.5 Ang II, BDNF and TRPC3
The activating effect of Ang II on PVN neurons is well documented. Inhibition of
Ang II signaling in the PVN attenuates the normal pressor response to acute stress,
showing that Ang II plays a significant role in modulating sympathetic responses.12 A
patch-clamp study by Cato & Toney (2003) demonstrated that Ang II excites neurons
in the PVN and induces a transient inward current through a suspected TRP channel.13
Ang II can also excite PVN neurons through mechanisms involving other ion
channels. For instance, Ang II triggers superoxide production via NADPH oxidase in
the hypothalamus, which inhibits delayed rectifier potassium currents, thereby
activating PVN neurons.23
There is also substantial evidence to support that BDNF plays an important role in
neuron excitability, particularly when it comes to sympathetic activity. Inhibition of
BDNF’s high-affinity receptor, TrkB, reduces stress-induced increases in blood
pressure in the PVN.57 Microinjection and overexpression of BDNF in the PVN
increases blood pressure, heart rate and other indicators of sympathetic activation.32,33
Other studies have shown that in the PVN, BDNF expression increases in
hypertensive conditions.32,33 There is also evidence to suggest a relationship between
BDNF and TRPC3. BDNF can activate post-synaptic TrkB receptors and depolarize
neurons through opening of suspected sodium channels and TRPC3.37,40 Moreover, in
the hippocampus, BDNF-induced currents require TRPC3, and TRPC3 surface
density is increased through a PI3-kinase dependent trafficking mechanism following
BDNF binding to TrkB.38
With this in mind, it was surprising that we were unable to demonstrate neuronal
activation using Ang II, DHF, GSK and a combination of Ang II and DHF in our
preparation. Moreover, inhibition of TRPC3 did not induce any significant changes in
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any of our parameters, which suggests that TRPC3 doesn’t play a role in the
“spontaneous” calcium fluctuations we saw in our control condition.
There are a few potential reasons as to why our results did not mirror our expectations
when it came to application of Ang II, DHF and GSK. In the slicing process, random
synaptic connections from the peri-PVN to the PVN could have been compromised.
This would drastically change the activity of PVN neurons, potentially altering their
normal in vivo responses to drugs, as their synaptic inputs would be modified. In our
experiments, we assumed that if peri-PVN connections were severed, PVN neurons
would be in a hyper-excitable state, as these neurons are typically under strong
inhibition by GABAergic peri-PVN inputs. As a result, we pre-treated slices with
GABA before application of Ang II to see if we would be able to induce neuronal
excitation this way. Application of Ang II following pre-treatment with GABA
showed promising results, where the number of active sites and cumulative intensity
tended to increase. These findings were likely not statistically significant due to the
small number of experiments we conducted for this condition. In future studies, we
could pre-treat slices with the inhibitory cocktail, isolating PVN neurons from periPVN inputs, to try and activate the neurons using Ang II, DHF and GSK.
In summary, our studies have shed light on intracellular Ca2+ events in PVN neurons
and demonstrated that this technique could further our understanding of PVN
regulatory mechanisms. More studies and analysis will be needed to categorize
neuronal behaviors in the PVN, particularly in response to Ang II and DHF. These
future studies will hopefully allow us to elucidate the role of Ang II, BDNF, TRPC3
ion channels and their interactions.
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